Oppenheimer analyst Matthew Biegler lowered the price target on Turning Point Therapeutics Inc. (NASDAQ: TPTX) to $105.00 (from $115.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE